Skip to main content

Diabetes Mellitus

  • Chapter
  • First Online:
Metabolism of Human Diseases

Abstract

Diabetes mellitus (diabetes Greek, pass through/siphon; mellitus Latin, honey sweet) is a heterogeneous, multifactorial metabolic disorder characterized by chronic hyperglycemia. This is in part because insulin secretion is insufficient to maintain blood glucose levels in a physiological range [1]. On the one hand, diabetes can be diagnosed based on classical symptoms, i.e., polyuria (excessive production of urine) and polydipsia (excessive fluid intake) due to osmotic diuresis following glucosuria. The presence of glucose in urine is caused by blood glucose levels exceeding the capacity of renal tubular sodium-glucose linked transporters (SGLTs) to reabsorb glucose from the primary urine. On the other hand, the World Health Organization (WHO) criteria define diabetes either as a fasting blood glucose level at or above 7 mmol/l or as a level at or above 11.1 mmol/l 2 h post glucose challenge during an oral glucose tolerance test (2-h plasma glucose). The WHO further describes criteria of a prediabetes that comes with a strongly increased risk to develop diabetes. These include an impaired fasting blood glucose between 6.1 mmol/l and 6.9 mmol/l. In addition, an impaired glucose tolerance as indicated by a 2-h plasma glucose between 7.8 mmol/l and 11 mmol/l or glycated hemoglobin between 5.7 and 6.4 % points to prediabetes [2].

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 79.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 99.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Bluestone JA, Herold K, Eisenbarth G (2010) Genetics, pathogenesis and clinical interventions in type 1 diabetes. Nature 464:1293–1300

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. WHO;IDF (2006) Definition and diagnosis of diabetes mellitus and intermediate hyperglycemia; Report of a WHO/IDF consultation; ISBN: 978-92-4-159493-6

    Google Scholar 

  3. Sherwin R, Jastreboff AM (2012) Year in diabetes 2012: the diabetes tsunami. J Clin Endocrinol Metab 97:4293–4301

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. American Diabetes Association (2012) Diagnosis and classification of diabetes mellitus. Diabetes Care 35(Suppl 1):S64–S71

    Article  Google Scholar 

  5. American Diabetes Association (2004) Gestational diabetes mellitus. Diabetes Care 27(Suppl 1):S88–S90

    Google Scholar 

  6. Boitard C (2012) Pancreatic islet autoimmunity. Presse Med 41:e636–e650

    Article  PubMed  Google Scholar 

  7. Peng H, Hagopian W (2006) Environmental factors in the development of type 1 diabetes. Rev Endocr Metab Disord 7:149–162

    Article  PubMed  Google Scholar 

  8. Classen JB, Classen DC (2001) Vaccines and the risk of insulin-dependent diabetes (IDDM): potential mechanism of action. Med Hypotheses 57:532–538

    Article  CAS  PubMed  Google Scholar 

  9. Kahn SE, Hull RL, Utzschneider KM (2006) Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature 444:840–846

    Article  CAS  PubMed  Google Scholar 

  10. Kwon H, Pessin JE (2013) Adipokines mediate inflammation and insulin resistance. Front Endocrinol 4:71

    Article  Google Scholar 

  11. Coppari R, Bjorbaek C (2012) Leptin revisited: its mechanism of action and potential for treating diabetes. Nat Rev Drug Discov 11:692–708

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Stumvoll M, Goldstein BJ, van Haeften TW (2005) Type 2 diabetes: principles of pathogenesis and therapy. Lancet 365:1333–1346

    Article  CAS  PubMed  Google Scholar 

  13. Robertson RP, Harmon J, Tran PO, Poitout V (2004) Beta-cell glucose toxicity, lipotoxicity, and chronic oxidative stress in type 2 diabetes. Diabetes 53(Suppl 1):S119–S124

    Article  CAS  PubMed  Google Scholar 

  14. Siren R, Eriksson JG, Vanhanen H (2012) Waist circumference a good indicator of future risk for type 2 diabetes and cardiovascular disease. BMC Public Health 12:631

    Article  PubMed  PubMed Central  Google Scholar 

  15. Weir GC, Cavelti-Weder C, Bonner-Weir S (2011) Stem cell approaches for diabetes: towards beta cell replacement. Genome Med 3:61

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Laakso M (1999) Hyperglycemia and cardiovascular disease in type 2 diabetes. Diabetes 48:937–942

    Article  CAS  PubMed  Google Scholar 

  17. Yamagishi S (2011) Role of advanced glycation end products (AGEs) and receptor for AGEs (RAGE) in vascular damage in diabetes. Exp Gerontol 46:217–224

    Article  CAS  PubMed  Google Scholar 

  18. Furukawa M, Gohda T, Tanimoto M, Tomino Y (2013) Pathogenesis and novel treatment from the mouse model of type 2 diabetic nephropathy. Scientific World Journal 2013:928197

    Article  PubMed  PubMed Central  Google Scholar 

  19. Sho-ichi Y (2010) Role of advanced glycation end products (AGEs) and receptor for AGEs (RAGE) in vascular damage in diabetes. Exp Gerontol 46:217–224

    Google Scholar 

  20. Costa PZ, Soares R (2013) Neovascularization in diabetes and its complications. Unraveling the angiogenic paradox. Life sci 92:1037–1045

    Article  CAS  PubMed  Google Scholar 

  21. Lincoff AM, Wolski K, Nicholls SJ, Nissen SE (2007) Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA 298:1180–1188

    Article  CAS  PubMed  Google Scholar 

  22. Black C et al (2007) Meglitinide analogues for type 2 diabetes mellitus. Cochrane Database Syst Rev 18;(2):CD004654

    Google Scholar 

  23. Butler AE et al (2013) Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumors. Diabetes 62:2595–2604

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Riser Taylor S, Harris KB (2013) The clinical efficacy and safety of sodium glucose cotransporter-2 inhibitors in adults with type 2 diabetes mellitus. Pharmacotherapy 33:984–999

    Article  CAS  PubMed  Google Scholar 

  25. Yaturu S (2013) Insulin therapies: current and future trends at dawn. World J Diab 4:1–7

    Article  Google Scholar 

  26. Nathan DM et al (2009) Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 32:193–203

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Eckhard Lammert .

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer-Verlag Wien

About this chapter

Cite this chapter

Welters, A., Lammert, E. (2014). Diabetes Mellitus. In: Lammert, E., Zeeb, M. (eds) Metabolism of Human Diseases. Springer, Vienna. https://doi.org/10.1007/978-3-7091-0715-7_26

Download citation

Publish with us

Policies and ethics